MedPage Today on MSN

Tylenol orders down, leucovorin scripts up after Trump's unproven claims

White House messaging appeared to quickly influence medical practice ...

Health care roundup: Market talk

Find insight on Merck KGaA and Granules India in the latest Market Talks covering the health care sector.
Fierce Pharma

Fierce Pharma Asia—Kyowa ends OX40 program; Sanofi licenses first-in-class drug; BioNTech advances Duality ADC

Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug ...